{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:58:38Z","timestamp":1767664718268,"version":"build-2065373602"},"reference-count":353,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ctrv.2023.102526","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T02:36:03Z","timestamp":1677724563000},"page":"102526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada"],"prefix":"10.1016","volume":"115","author":[{"given":"Jason K.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard J.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent C.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly W.","family":"Burak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prosanto","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon M.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Sapisochin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Setareh","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Ramjeesingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Mujoomdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilidio","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Segedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102526_b0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40471-019-00188-3","article-title":"The changing epidemiology of primary liver cancer","volume":"6","author":"Petrick","year":"2019","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b0010","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2023.102526_b0015","first-page":"11","article-title":"Multidisciplinary management of patients with unresectable hepatocellular carcinoma: a critical appraisal of current evidence","author":"Gholam","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102526_b0020","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1038\/s41598-020-61028-9","article-title":"Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma","volume":"10","author":"Ho","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b0025","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102526_b0030","doi-asserted-by":"crossref","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv238\u201355.","DOI":"10.1093\/annonc\/mdy308"},{"key":"10.1016\/j.ctrv.2023.102526_b0035","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0045","doi-asserted-by":"crossref","unstructured":"Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, et al. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12:1758835920970840.","DOI":"10.1177\/1758835920970840"},{"key":"10.1016\/j.ctrv.2023.102526_b0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b0055","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ajg.2015.389","article-title":"Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma","volume":"111","author":"Giannini","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ctrv.2023.102526_b0065","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000367768","article-title":"Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B","volume":"5","author":"Kudo","year":"2016","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10620-019-05582-x","article-title":"Systemic management for advanced hepatocellular carcinoma: a review of the molecular pathways of carcinogenesis, current and emerging therapies, and novel treatment strategies","volume":"64","author":"Saffo","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ctrv.2023.102526_b0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2147\/JHC.S268300","article-title":"Percutaneous therapies for hepatocellular carcinoma: evolution of liver directed therapies","volume":"8","author":"Huber","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ctrv.2023.102526_b0085","article-title":"New frontiers in liver resection for hepatocellular carcinoma","volume":"2","author":"Allaire","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b0090","first-page":"10","article-title":"Liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a comprehensive review","author":"Toniutto","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2023.102526_b0095","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4254\/wjh.v7.i9.1184","article-title":"Intermediate hepatocellular carcinoma: how to choose the best treatment modality?","volume":"7","author":"Di Costanzo","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0100","doi-asserted-by":"crossref","unstructured":"Chen X, Lai L, Ye J, Li L. Downstaging therapies for unresectable hepatocellular carcinoma prior to hepatic resection: a systematic review and meta-analysis. Front Oncol 2021;11.","DOI":"10.3389\/fonc.2021.740762"},{"key":"10.1016\/j.ctrv.2023.102526_b0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0115","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102526_b0120","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000367743","article-title":"Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma","volume":"4","author":"Arizumi","year":"2015","journal-title":"Liver cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000365993","article-title":"Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization","volume":"87","author":"Ogasawara","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2023.102526_b0135","doi-asserted-by":"crossref","first-page":"368 -","DOI":"10.1200\/JCO.2018.36.4_suppl.368","article-title":"Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): an exploratory analysis of OPTIMIS\u2014an international observational study assessing the use of sorafenib after TACE","volume":"36","author":"Kudo","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2023.102526_b0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3350\/cmh.2019.0021n","article-title":"Switching to systemic therapy after locoregional treatment failure: definition and best timing","volume":"26","author":"Ogasawara","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0150","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1365-2036.2006.02932.x","article-title":"Systematic review: evidence-based management of hepatocellular carcinoma\u2013an updated analysis of randomized controlled trials","volume":"23","author":"Lopez","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2023.102526_b0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/JMDH.S128629","article-title":"The importance of a multidisciplinary approach to hepatocellular carcinoma","volume":"10","author":"Siddique","year":"2017","journal-title":"J Multidiscip Healthc"},{"key":"10.1016\/j.ctrv.2023.102526_b0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cld.1068","article-title":"The Multidisciplinary Management of Hepatocellular Carcinoma","volume":"17","author":"Salgia","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b0165","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cgh.2011.11.008","article-title":"Multidisciplinary management of hepatocellular carcinoma","volume":"10","author":"Guy","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2014.03.038","article-title":"Building the multidisciplinary team for management of patients with hepatocellular carcinoma","volume":"13","author":"Naugler","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0175","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MEG.0b013e32835e33bb","article-title":"Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective","volume":"25","author":"Colombo","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0180","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jacr.2018.04.021","article-title":"Radiologist quality assurance by nonradiologists at tumor board","volume":"15","author":"Masch","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0185","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1245\/s10434-013-3413-8","article-title":"Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome","volume":"21","author":"Yopp","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/13651820802356572","article-title":"Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival","volume":"10","author":"Chang","year":"2008","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ctrv.2023.102526_b0195","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/MCG.0000000000000825","article-title":"Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival","volume":"51","author":"Agarwal","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ctrv.2023.102526_b0200","doi-asserted-by":"crossref","first-page":"e0210730","DOI":"10.1371\/journal.pone.0210730","article-title":"Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients","volume":"14","author":"Sinn","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2023.102526_b0205","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jso.24500","article-title":"Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings","volume":"115","author":"Charriere","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0210","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","article-title":"Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality","volume":"152","author":"Serper","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b0215","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31187","article-title":"Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy","volume":"72","author":"Vitale","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0220","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00432-021-03528-3","article-title":"Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities","volume":"147","author":"Wehling","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0225","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.30185","article-title":"Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study","volume":"68","author":"Vitale","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0230","first-page":"11","article-title":"Defining the role of immunotherapy in the curative treatment of locoregionally advanced head and neck cancer: promises, challenges, and opportunities","author":"Saddawi-Konefka","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0235","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41416-021-01485-9","article-title":"Advances in the curative management of oesophageal cancer","volume":"126","author":"Bolger","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0240","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s12325-021-01675-0","article-title":"Curative-intent treatment with durvalumab in early-stage cancers","volume":"38","author":"Melillo","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2023.102526_b0245","first-page":"13","article-title":"Locoregional treatments for bridging and downstaging HCC to liver transplantation","author":"Crocetti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102526_b0250","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.3747\/co.27.7171","article-title":"Current locoregional therapies and treatment strategies in hepatocellular carcinoma","volume":"27","author":"Cardarelli-Leite","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0255","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32613","article-title":"Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF\/TKI and immunotherapy","author":"Tran","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0260","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000519749","article-title":"A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0265","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0270","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-019-0253-x","article-title":"Global consultation on cancer staging: promoting consistent understanding and use","volume":"16","author":"Brierley","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/OP.21.00227","article-title":"Redefining intermediate-stage HCC treatment in the era of immune therapies","volume":"18","author":"Brar","year":"2022","journal-title":"JCO Oncology Practice"},{"key":"10.1016\/j.ctrv.2023.102526_b0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0290","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000507370","article-title":"A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0295","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO","volume":"31","author":"Chen","year":"2020","journal-title":"MOS and SSO Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0300","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hep Intl"},{"key":"10.1016\/j.ctrv.2023.102526_b0305","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/j.hpb.2019.10.1690","article-title":"Curative treatment for intermediate stage Hepatocellular carcinoma in Barcelona clinic liver cancer staging classification","volume":"21","author":"Paibulparadorn","year":"2019","journal-title":"HPB"},{"key":"10.1016\/j.ctrv.2023.102526_b0310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000502905","article-title":"A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0315","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jvir.2016.04.014","article-title":"Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome","volume":"27","author":"Miyayama","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0320","first-page":"12","article-title":"Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes of an iterative treatment","author":"Pelizzaro","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0325","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.3390\/app10207337","article-title":"Treatment strategy of transarterial chemoembolization for hepatocellular carcinoma","volume":"10","author":"Miyayama","year":"2020","journal-title":"Appl Sci"},{"key":"10.1016\/j.ctrv.2023.102526_b0330","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/cancers12071914","article-title":"Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies","volume":"12","author":"Makary","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2023.102526_b0335","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.12998\/wjcc.v9.i21.5754","article-title":"Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis","volume":"9","author":"Long","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ctrv.2023.102526_b0340","doi-asserted-by":"crossref","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Aikata H, Izumi N, et al. TACTICS: final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). Am Soc Clin Oncol 2021.","DOI":"10.1200\/JCO.2021.39.3_suppl.270"},{"key":"10.1016\/j.ctrv.2023.102526_b0345","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2023.102526_b0350","doi-asserted-by":"crossref","unstructured":"Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study. Cancers (Basel) 2019;11.","DOI":"10.20944\/preprints201906.0285.v1"},{"key":"10.1016\/j.ctrv.2023.102526_b0355","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1159\/000510299","article-title":"Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma","volume":"9","author":"Kawamura","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0360","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505189","article-title":"A new era in systemic therapy for hepatocellular carcinoma: atezolizumab plus bevacizumab combination therapy","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","article-title":"Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J Carcinogenesis"},{"key":"10.1016\/j.ctrv.2023.102526_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103747","article-title":"Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma","volume":"25","author":"Huang","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ctrv.2023.102526_b0375","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000367754","article-title":"Tumor heterogeneity in hepatocellular carcinoma: facing the challenges","volume":"5","author":"Lu","year":"2016","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0380","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-7-2","article-title":"Clinical implications and utility of field cancerization","volume":"7","author":"Dakubo","year":"2007","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0385","first-page":"963","article-title":"\u201cField cancerization\u201d in oral stratified squamous epithelium","volume":"6","author":"Slaughter","year":"1953","journal-title":"Clin Implicat Multicent Origin Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0390","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/archsurg.136.5.528","article-title":"Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma","volume":"136","author":"Bilimoria","year":"2001","journal-title":"Arch Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b0395","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Hoshida","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102526_b0400","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/onc.2016.340","article-title":"A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets","volume":"36","author":"Wijetunga","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2023.102526_b0405","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1245\/s10434-012-2336-0","article-title":"Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes","volume":"19","author":"Kneuertz","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0410","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jmri.27553","article-title":"Hepatocellular carcinoma with atypical imaging features: review of the morphologic hepatocellular carcinoma subtypes with radiology-pathology correlation","volume":"55","author":"Bello","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ctrv.2023.102526_b0415","doi-asserted-by":"crossref","unstructured":"Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update. Cancers (Basel) 2020;12.","DOI":"10.3390\/cancers12040791"},{"key":"10.1016\/j.ctrv.2023.102526_b0420","doi-asserted-by":"crossref","first-page":"17","DOI":"10.20517\/2394-5079.2021.138","article-title":"Role of locoregional therapies in the management of patients with hepatocellular carcinoma","volume":"8","author":"Kung","year":"2022","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.ctrv.2023.102526_b0425","doi-asserted-by":"crossref","first-page":"121 -","DOI":"10.1186\/s13244-019-0801-z","article-title":"Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review","volume":"10","author":"Voizard","year":"2019","journal-title":"Insights Imaging"},{"key":"10.1016\/j.ctrv.2023.102526_b0430","first-page":"6","article-title":"Intra-arterial therapies for hepatic malignancies","author":"Kim","year":"2017","journal-title":"J Target Ther Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0435","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4240\/wjgs.v12.i3.85","article-title":"Evolution and current status of the subclassification of intermediate hepatocellular carcinoma","volume":"12","author":"Yi","year":"2020","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b0440","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/jgh.12686","article-title":"Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma","volume":"30","author":"Wang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0445","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/liv.13487","article-title":"New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0450","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/liv.12696","article-title":"Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients","volume":"35","author":"Weinmann","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0455","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jfma.2021.07.003","article-title":"Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ctrv.2023.102526_b0460","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1159\/000439290","article-title":"Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's subclassification (kinki criteria)","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b0465","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0470","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.transproceed.2012.07.006","article-title":"Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma","volume":"44","author":"de Ataide","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ctrv.2023.102526_b0475","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3748\/wjg.v28.i23.2561","article-title":"Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma","volume":"28","author":"Silk","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2023.102526_b0480","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/hepr.13048","article-title":"Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization","volume":"48","author":"Yasui","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ctrv.2023.102526_b0485","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2011.10.021","article-title":"Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines","volume":"56","author":"Takayasu","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0490","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-016-9771-0","article-title":"Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers","volume":"11","author":"Kimura","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0495","first-page":"11","article-title":"Combination of Mac-2 binding protein glycosylation isomer and up-to-seven criteria as a useful predictor for Child-Pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma","author":"Eso","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102526_b0500","doi-asserted-by":"crossref","DOI":"10.14218\/JCTH.2021.00336","article-title":"Subsequent treatment after transarterial chemoembolization failure\/refractoriness: a review based on published evidence","author":"Zhang","year":"2022","journal-title":"J Clin Translat Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2023.102526_b0505","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000368143","article-title":"Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ","volume":"87","author":"Arizumi","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2023.102526_b0510","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000343867","article-title":"How to define transarterial chemoembolization failure or refractoriness: a European perspective","volume":"3","author":"Raoul","year":"2014","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0515","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/liv.12314","article-title":"Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel","volume":"34","author":"Cheng","year":"2014","journal-title":"Liver Int"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2023.102526_b0520","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000368142","article-title":"Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update","volume":"87","author":"Kudo","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2023.102526_b0525","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/liv.12083","article-title":"Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)","volume":"33","author":"Park","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0530","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0535","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol:JCO.22.00392."},{"key":"10.1016\/j.ctrv.2023.102526_b0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2023.102526_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.106094","article-title":"Clinical consensus statement: selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia","volume":"102","author":"Liu","year":"2022","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b0550","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1007\/s00261-021-03095-8","article-title":"Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma","volume":"46","author":"Alem","year":"2021","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.ctrv.2023.102526_b0555","doi-asserted-by":"crossref","first-page":"W263","DOI":"10.2214\/AJR.17.17993","article-title":"Imaging of hepatocellular carcinoma response after (90)Y radioembolization","volume":"209","author":"Semaan","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2023.102526_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cld.802","article-title":"Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"13","author":"Marrero","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b0565","doi-asserted-by":"crossref","unstructured":"Burak KW, Sherman M. Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178\u201384.","DOI":"10.1155\/2015\/824263"},{"key":"10.1016\/j.ctrv.2023.102526_b0570","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0575","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","article-title":"Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis","volume":"35","author":"Malagari","year":"2012","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0580","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0585","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00270-011-0287-7","article-title":"Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations","volume":"35","author":"Lencioni","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0590","unstructured":"Klass D, Owen D, Buczkowski A, Chung SW, Scudamore CH, Weiss AA, et al. The effect of Doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation study. Anticancer Res 2014;34:3597\u2013606."},{"key":"10.1016\/j.ctrv.2023.102526_b0595","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","article-title":"Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"22","author":"Sacco","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0600","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000329602","article-title":"A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"34","author":"van Malenstein","year":"2011","journal-title":"Onkologie"},{"journal-title":"J Clin Oncol","year":"202038","author":"Ikeda","key":"10.1016\/j.ctrv.2023.102526_b0605"},{"key":"10.1016\/j.ctrv.2023.102526_b0610","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0615","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/CEJ.0000000000000623","article-title":"Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early-and intermediate-stage hepatocellular carcinoma","volume":"30","author":"Gjoreski","year":"2021","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ctrv.2023.102526_b0620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246172","article-title":"Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"13","author":"Bzeizi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102526_b0625","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2217\/hep.13.18","article-title":"Chemoembolization with DC Bead\u2122 for the treatment of hepatocellular carcinoma: an update","volume":"1","author":"Malagari","year":"2014","journal-title":"Hepat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0630","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00270-005-0171-4","article-title":"Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization","volume":"29","author":"Sato","year":"2006","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0635","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b0640","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/cncr.29275","article-title":"Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis","volume":"121","author":"Kokabi","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0645","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0650","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"Pitton","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1155\u201363","key":"10.1016\/j.ctrv.2023.102526_b0655","first-page":"e2","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b0660","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2023.102526_b0665","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00270-019-02404-5","article-title":"Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus","volume":"43","author":"Cardarelli-Leite","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0670","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","article-title":"Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis","volume":"39","author":"Lobo","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0675","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215430","article-title":"Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis","volume":"13","author":"Zane","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102526_b0680","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","article-title":"Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma","volume":"33","author":"Kallini","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2023.102526_b0685","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2214\/AJR.15.14802","article-title":"Transarterial chemoembolization and (90)Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease","volume":"205","author":"Fidelman","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2023.102526_b0690","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s00261-018-1802-y","article-title":"Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma","volume":"44","author":"Kirchner","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.ctrv.2023.102526_b0695","doi-asserted-by":"crossref","unstructured":"Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11:1358\u201365.e1.","DOI":"10.1016\/j.cgh.2013.04.028"},{"key":"10.1016\/j.ctrv.2023.102526_b0700","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b0705","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0710","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0715","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0720","article-title":"The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future","author":"Sposito","year":"20187487","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.ctrv.2023.102526_b0725","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0730","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"issue":"1662\u201370","key":"10.1016\/j.ctrv.2023.102526_b0735","first-page":"e4","article-title":"Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma","volume":"29","author":"Allimant","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0740","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0745","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0750","doi-asserted-by":"crossref","unstructured":"Lam M, Salem R, Garin E. Abstract No. LB02 A global study of advanced dosimetry in the treatment of hepatocellular carcinoma with Yttrium-90 glass microspheres: analyses from the TARGET study. J Vasc Intervent Radiol 2021;32:S42.","DOI":"10.1016\/j.jvir.2021.03.096"},{"key":"10.1016\/j.ctrv.2023.102526_b0755","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/liv.13220","article-title":"High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization","volume":"37","author":"Garin","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0760","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","article-title":"(90)Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort","volume":"59","author":"Abouchaleh","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2023.102526_b0765","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0770","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0775","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0780","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0785","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study","volume":"5","author":"Kolligs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b0790","doi-asserted-by":"crossref","first-page":"e0216935","DOI":"10.1371\/journal.pone.0216935","article-title":"Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival","volume":"14","author":"Somma","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2023.102526_b0795","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial","volume":"48","author":"Cheng","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0800","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0805","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00259-015-3210-7","article-title":"Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis","volume":"43","author":"Edeline","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2023.102526_b0810","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2967\/jnumed.121.261954","article-title":"Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: analysis of the US National Cancer Database","volume":"62","author":"Ahn","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2023.102526_b0815","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","article-title":"Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma\u2014a randomized controlled trial","volume":"94","author":"Lin","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b0820","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0825","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/2050640616673516","article-title":"Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"5","author":"Facciorusso","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.ctrv.2023.102526_b0830","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0835","article-title":"A Randomized Controlled Trial of Transarterial Ethanol Ablation vs Transcatheter Arterial Chemoembolisation for Unresectable HCC","volume":"24","author":"Yu","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0840","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0845","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","article-title":"Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma","volume":"33","author":"Malagari","year":"2010","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b0850","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4","article-title":"Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma: a randomized controlled study","volume":"74","author":"Chang","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0855","doi-asserted-by":"crossref","unstructured":"Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992;31 Suppl:S1\u20136.","DOI":"10.1007\/BF00687096"},{"key":"10.1016\/j.ctrv.2023.102526_b0860","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/bjc.2013.85","article-title":"A randomised phase II\/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma","volume":"108","author":"Meyer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0865","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0870","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.2217\/fon-2020-0669","article-title":"Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing","volume":"16","author":"Rizzo","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0875","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000518584","article-title":"Adjuvant immunotherapy after curative treatment for hepatocellular carcinoma","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0880","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0885","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0890","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b0895","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0900","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gutjnl-2020-320692","article-title":"Changing TACTICS in intermediate HCC: TACE plus sorafenib","volume":"69","author":"Radu","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2023.102526_b0905","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1634\/theoncologist.2011-0313","article-title":"Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial","volume":"17","author":"Sansonno","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2023.102526_b0910","doi-asserted-by":"crossref","first-page":"S1312","DOI":"10.1016\/j.annonc.2021.08.2114","article-title":"LBA37 IMMUTACE: a biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0915","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s10147-022-02166-0","article-title":"New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma","volume":"27","author":"Kudo","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0920","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1007\/s00259-022-05920-8","article-title":"Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib","volume":"49","author":"\u00d6cal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2023.102526_b0925","first-page":"220","article-title":"Hepatocellular carcinoma: downstaging to liver transplantation as curative therapy","volume":"9","author":"Frankul","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0930","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772195","article-title":"Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0935","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2147\/JHC.S357313","article-title":"Neoadjuvant therapy for hepatocellular carcinoma","volume":"9","author":"Yin","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ctrv.2023.102526_b0940","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3390\/cancers14092056","article-title":"Immune checkpoint inhibitors as therapy to down-stage hepatocellular carcinoma prior to liver transplantation","volume":"14","author":"Katariya","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2023.102526_b0945","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2023.102526_b0950","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0955","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","article-title":"Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within milan criteria: a multicenter study","volume":"16","author":"Mehta","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b0960","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/jlts.2003.50147","article-title":"A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy","volume":"9","author":"Yao","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ctrv.2023.102526_b0965","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/hep.510270616","article-title":"Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power","volume":"27","author":"Llovet","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b0970","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1111\/j.1399-0012.2012.01668.x","article-title":"Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma","volume":"26","author":"Park","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ctrv.2023.102526_b0975","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2007-1007120","article-title":"Liver transplantation for hepatocellular carcinoma","volume":"19","author":"Bismuth","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b0980","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b0985","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1432-2277.2009.00980.x","article-title":"Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma","volume":"23","author":"Sandroussi","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.ctrv.2023.102526_b0990","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2023.102526_b0995","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.adro.2020.01.009","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma in patients with Child-Pugh B or C cirrhosis","volume":"5","author":"Lee","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1000","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","article-title":"Prospective randomized pilot study of Y90+\/-sorafenib as bridge to transplantation in hepatocellular carcinoma","volume":"61","author":"Kulik","year":"2014","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102526_b1010","first-page":"227","article-title":"Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma","volume":"2019","year":"2018","journal-title":"Gut Liver"},{"key":"10.1016\/j.ctrv.2023.102526_b1015","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13411","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update","volume":"49","author":"Kokudo","year":"2019","journal-title":"Hepatol Res"},{"issue":"Suppl. 15","key":"10.1016\/j.ctrv.2023.102526_b1020","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2018.36.15_suppl.4018","article-title":"Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis","volume":"36","author":"Peck-Radosavljevic","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1035","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102526_b1040","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1045","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1050","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1055","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022:EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"10.1016\/j.ctrv.2023.102526_b1060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102526_b1065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1070","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2021.39.3_suppl.268","article-title":"Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the randomized, phase III KEYNOTE-240 study","volume":"39(Suppl. 3)","author":"Merle","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study","volume":"40(Suppl. 4)","author":"Qin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jnci\/djaa119","article-title":"Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review","volume":"113","author":"Lim","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2023.102526_b1095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000516605","article-title":"Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: pooled results from two phase 3 studies (REACH and REACH-2)","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1100","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.3390\/curroncol28060367","article-title":"Report from the Western Canadian Gastrointestinal cancer consensus conference virtual education series-transition from local to system therapy and optimal sequencing of systemic therapy for HCC","volume":"28","author":"Zaidi","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1105","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/hep4.1927","article-title":"Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC","volume":"6","author":"Sharma","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ctrv.2023.102526_b1110","doi-asserted-by":"crossref","first-page":"e16173","DOI":"10.1200\/JCO.2021.39.15_suppl.e16173","article-title":"PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: an open-label, non-randomized, phase IV study","volume":"39(Suppl. 15)","author":"Zhang","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2022.01.122","article-title":"Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function","volume":"54","author":"Cabibbo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b1120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO Clinical Practice Guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.semradonc.2018.06.005","article-title":"Radiotherapy for hepatocellular carcinoma","volume":"28","author":"Yu","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4254\/wjh.v7.i1.101","article-title":"Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review","volume":"7","author":"Kalogeridi","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.04.024","article-title":"Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion","volume":"134","author":"Mathew","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1140","doi-asserted-by":"crossref","first-page":"e79854","DOI":"10.1371\/journal.pone.0079854","article-title":"Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma","volume":"8","author":"Yoon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2023.102526_b1145","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00432-020-03389-2","article-title":"Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity","volume":"147","author":"Loi","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4103\/ijc.IJC_156_17","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: experience from a tertiary cancer care center in India","volume":"54","author":"Madhavan","year":"2017","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhepr.2019.05.004","article-title":"Radiotherapy for HCC: ready for prime time?","volume":"1","author":"Bang","year":"2019","journal-title":"Jhep Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b1160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","article-title":"Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial","volume":"4","author":"Feng","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1165","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.radonc.2018.01.004","article-title":"A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy","volume":"126","author":"Moon","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1175","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.prro.2015.02.007","article-title":"Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1\u20132 trial of stereotactic body radiation therapy","volume":"5","author":"Lasley","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1180","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","article-title":"The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1185","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/cncr.27533","article-title":"Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization","volume":"118","author":"Kang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1190","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i\u2013ii study","volume":"45","author":"M\u00e9ndez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1195","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2023.102526_b1200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.005","article-title":"Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"131","author":"Rim","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1205","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1754-9485.13184","article-title":"Stereotactic body radiotherapy in the management of hepatocellular carcinoma: an Australian multi-institutional patterns of practice review","volume":"65","author":"Liu","year":"2021","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2020.04.019","article-title":"Stereotactic body radiotherapy for hepatocellular carcinoma-still searching for a role","volume":"73","author":"Meyer","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2018.12.013","article-title":"Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma","volume":"131","author":"Kim","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1220","unstructured":"Hara K, Takeda A, Tsurugai Y, Sanuki N, Saigusa Y, Maeda S, et al. Clinical Outcomes after treatment for hepatocellular carcinoma, stereotactic body radiotherapy vs radiofrequency ablation: a propensity score-matched analysis. Hepatology: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2018. p. 848A-A."},{"key":"10.1016\/j.ctrv.2023.102526_b1225","doi-asserted-by":"crossref","unstructured":"Feng MU-S, Marshall VD, Parikh N. Use of radiofrequency ablation and stereotactic body radiotherapy for the treatment of hepatocellular carcinoma: an analysis of the SEER-Medicare database. Am Soc Clin Oncol 2016.","DOI":"10.1200\/jco.2016.34.4_suppl.463"},{"key":"10.1016\/j.ctrv.2023.102526_b1230","doi-asserted-by":"crossref","first-page":"13490","DOI":"10.3748\/wjg.v21.i48.13490","article-title":"Comparison of percutaneous radiofrequency ablation and CyberKnife\u00ae for initial solitary hepatocellular carcinoma: a pilot study","volume":"21","author":"Shiozawa","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2023.102526_b1235","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1240","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.2017.75.3228","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database","volume":"36","author":"Rajyaguru","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1245","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/hep.30591","article-title":"Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis","volume":"69","author":"Hara","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b1250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jso.24661","article-title":"External radiation or ablation for solitary hepatocellular carcinoma: a survival analysis of the SEER database","volume":"116","author":"Berger","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1255","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.adro.2015.12.003","article-title":"Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma","volume":"1","author":"Mohamed","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1260","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1754-9485.12754","article-title":"Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-Medicare","volume":"62","author":"Parikh","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1265","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1080\/0284186X.2019.1657942","article-title":"Stereotactic body radiation therapy for early-stage hepatocellular carcinoma\u2013a systematic review on outcome","volume":"58","author":"Dobrzycka","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1275","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01639","article-title":"Stereotactic body radiotherapy vs. radiofrequency ablation in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"10","author":"Pan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1280","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2021-0263","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis","author":"Zhang","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1285","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/02656736.2020.1843719","article-title":"Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2020","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ctrv.2023.102526_b1290","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2016.66.4458","article-title":"Is stereotactic body radiotherapy better than radiofrequency ablation for the treatment of hepatocellular carcinoma?","volume":"34","author":"Yang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1295","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2015.64.8097","article-title":"Can stereotactic body radiotherapy effectively treat hepatocellular carcinoma?","volume":"34","author":"Barry","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1300","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JHC.S284403","article-title":"Current understanding of ablative radiation therapy in hepatocellular carcinoma","volume":"8","author":"Mathew","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ctrv.2023.102526_b1305","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.15442","article-title":"Radiofrequency ablation versus stereotactic body radiation therapy for small (\u2264 3 cm) hepatocellular carcinoma: a retrospective comparison analysis","author":"Jeong","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1310","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","article-title":"Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma","volume":"73","author":"Kim","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1315","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1320","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/COC.0000000000000435","article-title":"Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity","volume":"41","author":"Baumann","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1325","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11901-020-00559-1","article-title":"Stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma","volume":"20","author":"Thomas","year":"2021","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b1330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2019.05.066","article-title":"Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma","volume":"105","author":"Shen","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2023.102526_b1335","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.653141","article-title":"Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)","volume":"11","author":"Brunner","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.839605","article-title":"Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory","volume":"12","author":"Xiang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1345","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijrobp.2016.02.027","article-title":"Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis","volume":"95","author":"Bush","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2023.102526_b1350","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/S0167-8140(21)00397-2","article-title":"OC-0373: SBRT versus TAE\/TACE in hepatocellular carcinoma: results from a phase III trial (NCT02323360)","volume":"152","author":"Comito","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1355","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.ijrobp.2018.07.496","article-title":"Patterns of care and effectiveness of stereotactic body radiation therapy and yttrium-90 radioembolization in unresected hepatocellular carcinoma: an NCDB analysis","volume":"102","author":"Ashamalla","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2023.102526_b1360","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/jgo.2015.10.04","article-title":"Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma","volume":"7","author":"Oladeru","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1365","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity","volume":"4","author":"Lewis","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b1370","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000490260","article-title":"Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysis","volume":"8","author":"Bettinger","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1375","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3350\/cmh.2020.0204","article-title":"Optimizing the management of intermediate-stage hepatocellular carcinoma: current trends and prospects","volume":"27","author":"Torimura","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1380","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"Ishizawa","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b1385","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000480385","article-title":"Current modalities for the assessment of future remnant liver function","volume":"33","author":"Rassam","year":"2017","journal-title":"Visc Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1390","doi-asserted-by":"crossref","DOI":"10.23736\/S2724-5691.22.09541-7","article-title":"Future remnant Liver optimization: preoperative assessment, volume augmentation procedures and management of PVE failure","author":"Cassese","year":"2022","journal-title":"Minerva Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1395","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0038-1660793","article-title":"Clinical assessment and management of portal hypertension","volume":"35","author":"Kibrit","year":"2018","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.ctrv.2023.102526_b1400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/HMER.S278077","article-title":"Approaches to the diagnosis of portal hypertension: non-invasive or invasive tests?","volume":"13","author":"Dajti","year":"2021","journal-title":"Hepat Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1405","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cld.2021.01.005","article-title":"Noninvasive detection of clinically significant portal hypertension in compensated advanced chronic liver disease","volume":"25","author":"Vuille-Lessard","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ctrv.2023.102526_b1410","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b1415","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.31557\/APJCP.2020.21.10.2903","article-title":"New hepatic resection criteria for intermediate-stage hepatocellular carcinoma can improve long-term survival: a retrospective, multicenter collaborative study","volume":"21","author":"Iida","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ctrv.2023.102526_b1420","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/SLA.0b013e31828329b8","article-title":"A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL\/AASLD recommendations?: An observational study of the HCC East-West study group","volume":"257","author":"Torzilli","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1425","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000449336","article-title":"Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)","volume":"5","author":"Ho","year":"2016","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1430","doi-asserted-by":"crossref","first-page":"e68193","DOI":"10.1371\/journal.pone.0068193","article-title":"Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2023.102526_b1435","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1440","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13304-019-00649-w","article-title":"Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases","volume":"71","author":"Di Sandro","year":"2019","journal-title":"Updates Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1445","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4143\/crt.2018.038","article-title":"Hepatic resection provides survival benefit for selected intermediate-stage (BCLC-B) hepatocellular carcinoma patients","volume":"51","author":"Zhaohui","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102526_b1450","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00423-017-1640-3","article-title":"Liver resection for HCC outside the BCLC criteria","volume":"403","author":"Bhandare","year":"2018","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1455","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.surg.2016.05.023","article-title":"Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma","volume":"160","author":"Wada","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2023.102526_b1460","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/s12885-021-08421-3","article-title":"Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification","volume":"21","author":"Yamamoto","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1465","doi-asserted-by":"crossref","unstructured":"Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691\u2013700.e3.","DOI":"10.1053\/j.gastro.2014.02.032"},{"key":"10.1016\/j.ctrv.2023.102526_b1470","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","article-title":"Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT","volume":"61","author":"Yin","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1475","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1245\/s10434-011-2060-1","article-title":"Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis","volume":"19","author":"Hsu","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1480","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcrpr.2015.03.001","article-title":"Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma","volume":"3","author":"Lin","year":"2016","journal-title":"J Cancer Res Pract"},{"key":"10.1016\/j.ctrv.2023.102526_b1485","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.hpb.2019.12.011","article-title":"Treatment of hepatocellular carcinoma beyond the Milan criteria. A weighted comparative study of surgical resection versus chemoembolization","volume":"22","author":"Famularo","year":"2020","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ctrv.2023.102526_b1490","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1186\/s12885-018-4557-5","article-title":"Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study","volume":"18","author":"Zhong","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1495","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00268-020-05830-6","article-title":"Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan","volume":"45","author":"Aoki","year":"2021","journal-title":"World J Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1500","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijsu.2018.03.051","article-title":"Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: a propensity-matching cohort study","volume":"54","author":"Zhang","year":"2018","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1505","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/bjs.10541","article-title":"Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma","volume":"104","author":"Kim","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1510","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/cas.13257","article-title":"Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: a multicenter study from Japan","volume":"108","author":"Tada","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2023.102526_b1515","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/SLA.0000000000003192","article-title":"Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide survey","volume":"272","author":"Fukami","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1520","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00268-010-0598-x","article-title":"Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice?","volume":"34","author":"Lin","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1525","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.618937","article-title":"Hepatic resection versus transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a cohort study","volume":"11","author":"Lu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1530","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000505093","article-title":"Comparison of partial hepatectomy and transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Labgaa","year":"2020","journal-title":"Liver cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1535","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.hpb.2017.10.004","article-title":"Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"20","author":"Liang","year":"2018","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ctrv.2023.102526_b1540","doi-asserted-by":"crossref","unstructured":"Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986\u201394.e3; quiz e14\u20135.","DOI":"10.1053\/j.gastro.2012.05.052"},{"key":"10.1016\/j.ctrv.2023.102526_b1545","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14218\/JCTH.2019.00050","article-title":"Liver transplantation beyond Milan criteria","volume":"8","author":"Lingiah","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1550","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.suronc.2019.10.006","article-title":"Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium","volume":"33","author":"Degroote","year":"2020","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tgh.2020.01.06","article-title":"Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"6","author":"Bento de Sousa","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1560","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2023.102526_b1565","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1440-1746.2010.06335.x","article-title":"Current controversies surrounding liver transplantation for hepatocellular carcinoma","volume":"25","author":"Silva","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1570","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1526924817746686","article-title":"Value of HCC-MELD score in patients with hepatocellular carcinoma undergoing liver transplantation","volume":"28","author":"Guerrini","year":"2018","journal-title":"Prog Transplant"},{"key":"10.1016\/j.ctrv.2023.102526_b1575","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3748\/wjg.v24.i32.3626","article-title":"Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions","volume":"24","author":"Pavel","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2023.102526_b1580","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b1585","first-page":"6","article-title":"Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis","author":"Lozanovski","year":"2022","journal-title":"BJS Open"},{"key":"10.1016\/j.ctrv.2023.102526_b1590","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.27787","article-title":"Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation","volume":"62","author":"Toso","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b1595","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1159\/000506752","article-title":"Liver transplantation for extended criteria hepatocellular carcinoma using stable response to locoregional therapy and alpha-fetoprotein as selection criteria","volume":"36","author":"Schoenberg","year":"2020","journal-title":"Visceral Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1600","doi-asserted-by":"crossref","first-page":"e934924","DOI":"10.12659\/AOT.934924","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: risk factors and predictive models","volume":"27","author":"Stra\u015b","year":"2022","journal-title":"Ann Transplant"},{"key":"10.1016\/j.ctrv.2023.102526_b1605","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4254\/wjh.v11.i3.261","article-title":"Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation","volume":"11","author":"Filgueira","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1610","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ctrv.2023.102526_b1615","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jhep.2019.07.016","article-title":"Canadian liver transplant allocation for hepatocellular carcinoma","volume":"71","author":"Brahmania","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1620","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2018.12.029","article-title":"Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation","volume":"70","author":"Goldaracena","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1625","doi-asserted-by":"crossref","first-page":"e213112","DOI":"10.1001\/jamasurg.2021.3112","article-title":"Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant","volume":"156","author":"Lai","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1630","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/14656566.2018.1498843","article-title":"How to select the appropriate \u201cneoadjuvant therapy\u201d for hepatocellular carcinoma","volume":"19","author":"Liu","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ctrv.2023.102526_b1635","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: a systematic review and pooled analysis","volume":"21","author":"Parikh","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ctrv.2023.102526_b1640","doi-asserted-by":"crossref","unstructured":"Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, et al. Liver transplantation for hepatocellular carcinoma. In: Working group report from the ILTS transplant oncology consensus conference. Transplantation; 2020;104:1136\u201342.","DOI":"10.1097\/TP.0000000000003174"},{"key":"10.1016\/j.ctrv.2023.102526_b1645","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1600-6143.2008.02409.x","article-title":"Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria","volume":"8","author":"Ravaioli","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2023.102526_b1650","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jso.21159","article-title":"Treatment and prognosis of hepatocellular carcinoma: a population based study in France","volume":"98","author":"Borie","year":"2008","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2023.102526_b1655","doi-asserted-by":"crossref","first-page":"4756147","DOI":"10.1155\/2018\/4756147","article-title":"Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery","volume":"2018","author":"Shiina","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1660","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/cncr.24196","article-title":"Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors","volume":"115","author":"Yin","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1665","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/jgh.13586","article-title":"Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma","volume":"32","author":"Nouso","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1670","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2214\/AJR.17.18177","article-title":"Transcatheter arterial chemoembolization with or without radiofrequency ablation: outcomes in patients with Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma","volume":"210","author":"Hirooka","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2023.102526_b1675","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000502479","article-title":"Treatment of intermediate-stage hepatocellular carcinoma in Japan: position of curative therapies","volume":"9","author":"Kariyama","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1680","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hpb.12214","article-title":"Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma","volume":"16","author":"Ho","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.ctrv.2023.102526_b1685","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","article-title":"Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial","volume":"3","author":"Vietti Violi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1690","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40880-017-0183-x","article-title":"Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma","volume":"36","author":"Xu","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.ctrv.2023.102526_b1695","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1148\/radiol.2232010775","article-title":"Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy","volume":"223","author":"Shibata","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2023.102526_b1700","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s00464-014-3617-4","article-title":"Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience","volume":"28","author":"Abdelaziz","year":"2014","journal-title":"Surg Endosc"},{"key":"10.1016\/j.ctrv.2023.102526_b1705","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hep.23965","article-title":"Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study","volume":"53","author":"Rossi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2023.102526_b1710","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41598-021-03802-x","article-title":"Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial","volume":"12","author":"Radosevic","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b1715","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/02656736.2018.1562571","article-title":"Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"36","author":"Tan","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ctrv.2023.102526_b1720","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.2147\/OTT.S204340","article-title":"Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis","volume":"12","author":"Glassberg","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2023.102526_b1725","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","article-title":"Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"Facciorusso","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ctrv.2023.102526_b1730","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14218\/JCTH.2018.00013","article-title":"Microwave ablation in intermediate hepatocellular carcinoma in cirrhosis: an Italian multicenter prospective study","volume":"6","author":"Giorgio","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1735","article-title":"Oncological outcomes of operative microwave ablation for intermediate stage hepatocellular carcinoma: experience in 246 consecutive patients","author":"Ryu","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ctrv.2023.102526_b1740","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/02656736.2020.1752400","article-title":"Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis","volume":"37","author":"Chen","year":"2020","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ctrv.2023.102526_b1745","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejro.2019.01.004","article-title":"Initial experience with irreversible electroporation of liver tumours","volume":"6","author":"Stillstr\u00f6m","year":"2019","journal-title":"Eur J Radiol Open"},{"key":"10.1016\/j.ctrv.2023.102526_b1750","doi-asserted-by":"crossref","first-page":"43687","DOI":"10.1038\/srep43687","article-title":"Percutaneous irreversible electroporation: long-term survival analysis of 71 patients with inoperable malignant hepatic tumors","volume":"7","author":"Niessen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2023.102526_b1755","doi-asserted-by":"crossref","first-page":"190","DOI":"10.14218\/JCTH.2021.00019","article-title":"Irreversible electroporation for hepatocellular carcinoma abutting the diaphragm: a prospective single-center study","volume":"10","author":"Ma","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ctrv.2023.102526_b1760","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102526_b1765","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:30:28Z","timestamp":1759656628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":353,"alternative-id":["S0305737223000178"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102526","relation":{},"ISSN":["0305-7372"],"issn-type":[{"type":"print","value":"0305-7372"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102526"}}